Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

Fig. 6

Evaluation of CD138+ miR-25 levels improves risk-stratification and results to superior clinical benefit in MM prognosis. Kaplan–Meier survival curves for the overall survival (OS) of MM patients according to CD138+ expression of miR-25 in combination with R-ISS stage A, high-risk cytogenetics B and response to 1st line therapy C. p-values calculated by log-rank test. sCR: stringent complete response, CR: complete response and VGPR: very good partial response, PR: partial response, SD: stable disease, PD: progressive disease

Back to article page